These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18520515)

  • 1. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody).
    Foerster CG; Cursiefen C; Kruse FE
    Cornea; 2008 Jun; 27(5):612-4. PubMed ID: 18520515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment].
    Förster CG; Cursiefen C; Kruse FE
    Ophthalmologe; 2008 Mar; 105(3):269-73. PubMed ID: 18350301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.
    Bambury R; McCaffrey JA
    Clin Colorectal Cancer; 2009 Oct; 8(4):235. PubMed ID: 19822516
    [No Abstract]   [Full Text] [Related]  

  • 4. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
    Rodriguez NA; Ascaso FJ
    J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe acneiform eruption induced by cetuximab (Erbitux).
    Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
    Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dry eye].
    Cursiefen C
    Ophthalmologe; 2013 Jun; 110(6):498-9. PubMed ID: 23783991
    [No Abstract]   [Full Text] [Related]  

  • 9. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.
    Cohen PR; Escudier SM; Kurzrock R
    Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab-associated pulmonary toxicity.
    Chua W; Peters M; Loneragan R; Clarke S
    Clin Colorectal Cancer; 2009 Apr; 8(2):118-20. PubMed ID: 19739274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
    Zhang G; Basti S; Jampol LM
    Cornea; 2007 Aug; 26(7):858-60. PubMed ID: 17667622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
    Braiteh F; Kurzrock R; Johnson FM
    J Clin Oncol; 2008 Jul; 26(20):3460-2. PubMed ID: 18612164
    [No Abstract]   [Full Text] [Related]  

  • 13. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
    Gencoglan G; Ceylan C
    Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing.
    Hori K; Sotozono C; Hamuro J; Yamasaki K; Kimura Y; Ozeki M; Tabata Y; Kinoshita S
    J Control Release; 2007 Apr; 118(2):169-76. PubMed ID: 17289206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
    Márquez G; Herrera-Acosta E; Vidal I; Galvany L; Iglesias M; Umbert P
    Int J Dermatol; 2009 Jan; 48(1):97-8. PubMed ID: 19126063
    [No Abstract]   [Full Text] [Related]  

  • 16. Trichomegaly Induced by Cetuximab: Case Series and Review the Literature.
    Koksal UI; Pilanci KN; Ordu C; Okutur K; Saglam S; Demir G
    Am J Ther; 2016; 23(5):e1226-9. PubMed ID: 26079631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
    Saif MW; Gnanaraj J
    Cutan Ocul Toxicol; 2010 Mar; 29(1):62-6. PubMed ID: 19954400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab-induced hypertrichosis of the scalp and eyelashes.
    Vano-Galvan S; Ríos-Buceta L; Ma DL; Fernández-Chacón C; Viera JC; Jaén P
    J Am Acad Dermatol; 2010 Mar; 62(3):531-3. PubMed ID: 20159332
    [No Abstract]   [Full Text] [Related]  

  • 20. Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody.
    Kerob D; Dupuy A; Reygagne P; Levy A; Morel P; Bernard BA; Lebbé C
    Arch Dermatol; 2006 Dec; 142(12):1656-7. PubMed ID: 17179005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.